These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7528391)

  • 21. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
    el Etreby MF; Nishino Y; Habenicht UF; Henderson D
    J Androl; 1991; 12(6):403-14. PubMed ID: 1722797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 1992; 147(1-2):125-35; discussion 135-7. PubMed ID: 1384903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical therapy for benign prostatic hyperplasia.
    Keetch DW; Andriole GL
    AJR Am J Roentgenol; 1995 Jan; 164(1):11-5; discussion 16-7. PubMed ID: 7527995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen deprivation therapy for precancerous lesions of the prostate.
    Hull D; Bostwick DG
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J
    Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is transurethral microwave thermotherapy an alternative to medical therapy for patients with benign prostatic hyperplasia?
    Djavan B
    Tech Urol; 2000 Dec; 6(4):300-6. PubMed ID: 11108570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia.
    Harkaway RC; Issa MM
    Prostate Cancer Prostatic Dis; 2006; 9(3):204-14. PubMed ID: 16755276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
    Seftel A; Rosen R; Kuritzky L
    Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm.
    Barkin J
    Can J Urol; 2008 Aug; 15 Suppl 1():21-30; discussion 30. PubMed ID: 18700062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Androgen deprivation in benign prostatic hypertrophy].
    Tenaglia R; Nicolai M; Di Federico G; Iantorno R; Zezza A; Lombardi G
    J Urol (Paris); 1993; 99(6):296-8. PubMed ID: 7516371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current treatment of BPH.
    Roylance P; Gibelin B; Espié J
    Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
    Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV
    Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benign prostatic hyperplasia: use of drug therapy in primary care.
    Beduschi R; Beduschi MC; Oesterling JE
    Geriatrics; 1998 Mar; 53(3):24-8, 33-4, 37-40. PubMed ID: 9511773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.